External control arms: how and when
When your trial has no suitable control you can build one from outside it. The first decision shapes everything that follows: patient-level data, or summary data?
Evidax Insights
When your trial has no suitable control you can build one from outside it. The first decision shapes everything that follows: patient-level data, or summary data?
Regulators, HTA bodies and evidence-synthesis standard-setters have started to say how AI may be used in evidence generation. Across very different institutions, they converge on the same answer.
A field guide to indirect treatment comparisons: why you reach for one, the toolbox from Bucher to ML-NMR, who accepts them, and the handful of things that separate a robust ITC from a fragile one.
The EU Joint Clinical Assessment gives you 100 days to answer comparative questions you did not choose. Here is how it works, and what it changes about when evidence planning has to start.